Skip to main content

Table 3 Population parameter estimates using mixed effects modelling (standard deviation)

From: (R)-[11C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus

Parameter estimates

Estimate

Inter-individual variability

Covariate tariquidar

Covariate kainate

Covariate weight

Plasma

     

Vc (mL)

22.8 (2.41)

0.175 (0.085)

-

-

-

Vp1 (mL)

504 (40.7)

 

1.20 (0.119)

-

-

Vp2 (mL)

70.2 (9.91)

0.036 (0.034)

-

-

-

CL (mL· min-1)

14.7 (0.681)

0.065 (0.016)

-

-

1.98 (0.362)

Q1 (mL· min-1)

16.1 (1.75)

0.220 (0.073)

-

-

-

Q2 (mL· min-1)

22.7 (3.34)

0.220 (0.073)

-

-

-

Brain

  

-

 

-

Vbr1 (mL)

7.23 (2.00)

0.115 (0.054)

2.41 (0.505)

1.32 (0.416)

-

Vbr2 (mL)

10.7 (2.22)

0.115 (0.054)

-

-

-

Qin (mL· min-1)

1.75 (0.26)

-

12.0 (0.554)

-

-

Qout (mL· min-1)

1.81 (0.283)

-

-

-

-

Qbr (mL· min-1)

0.692 (0.143)

-

-

-

-

Residual errors

  

-

-

-

blood

0.118 (0.0152)

-

-

-

-

brain

0.226 (0.0354)

-

-

-

-

  1. Covariates for tariquidar co-administration and rat group were defined as θcovariate COVARIATE , where the COVARIATEs, i.e. kainate treatment or tariquidar co-administration was 1 and saline treated or vehicle co-administration 0. The numbers reported are thus the fractional differences.
  2. Covariate for weight was defined as (weight/0.3084)θcovariate , where weight represent the individual animal's weight in kg and 0.3084 was the average weight among all animals. See also equations 4 and 5.